Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraoperative Radiotherapy Combined With Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07870798Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Oct 2026
- Primary completion
- Dec 2027
01
Overview
Phase 2, randomised, open-label trial of serplulimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Pathological Complete Response. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07870798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07870798.